CRISPR Takes the Front Seat in CART-Cell Development

Area of Science:

• Oncology
• Immunotherapy
• Gene Therapy

Background:

• Chimeric antigen receptor T-cell (CART) immunotherapies are approved for certain hematological cancers, but autologous product manufacturing is costly and time-consuming.
• High relapse rates within a year and limited efficacy in solid tumors hinder CART therapy adoption.
• Significant toxicities and intrinsic T-cell limitations are further barriers to widespread CART-cell therapy.

Purpose of the Study:

• To review current strategies employing CRISPR/Cas systems for enhancing CART-cell therapy.
• To explore how CRISPR facilitates the development of "off-the-shelf" CART products.
• To summarize approaches for increasing CART-cell efficacy and minimizing treatment-associated toxicities.

Main Methods:

• Review of current literature on CRISPR/Cas applications in CART-cell engineering.
• Analysis of studies focusing on overcoming manufacturing, efficacy, and toxicity challenges.
• Synthesis of data on CRISPR-mediated modifications for improved CART-cell function.

Main Results:

• CRISPR/Cas systems show potential in engineering CART cells to address current limitations.
• Gene editing can facilitate the creation of allogeneic, "off-the-shelf" CART products.
• CRISPR-based strategies aim to enhance CART-cell persistence, tumor infiltration, and safety profiles.

Conclusions:

• CRISPR/Cas technology is a powerful tool for advancing CART-cell therapy.
• Genome editing holds promise for developing more accessible, effective, and safer CART-cell treatments for a broader patient population.
• Further research into CRISPR-engineered CART cells is crucial for overcoming existing therapeutic barriers.